<DOC>
	<DOCNO>NCT02224729</DOCNO>
	<brief_summary>This phase II trial study side effect well bendamustine hydrochloride , bortezomib , dexamethasone work treat patient newly diagnose multiple myeloma . Drugs use chemotherapy , bendamustine hydrochloride dexamethasone , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving bendamustine hydrochloride bortezomib dexamethasone may kill cancer cell .</brief_summary>
	<brief_title>Bendamustine Hydrochloride , Bortezomib , Dexamethasone Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish response rate induction therapy follow 4 cycle combination regimen bendamustine ( bendamustine hydrochloride ) , bortezomib dexamethasone ( BBd ) patient newly diagnose multiple myeloma . II . Describe tolerability toxicity regimen . III . Provide one-year progression-free survival one-year overall survival data follow therapeutic strategy . OUTLINE : Patients receive bendamustine hydrochloride intravenously ( IV ) 30 minute day 1 2 ; bortezomib subcutaneously ( SC ) day 1 , 8 , 15 , 22 ; dexamethasone orally ( PO ) day 1 , 8 , 15 , 22 . Treatment repeat every 35 day 4 course absence disease progression unacceptable toxicity . Patients achieve less good partial response ( VGPR ) 10 % bone marrow plasmacytosis may receive 2 additional course . NOTE : Patients require immediate reduction paraprotein course 1 receive bendamustine hydrochloride IV 30 minute day 1 2 ; bortezomib IV day 1 , 4 , 8 , 11 ; dexamethasone PO day 1-4 . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . New diagnosis multiple myeloma prior history systemic treatment ( Exceptions include corticosteroid , bisphosphonates , single agent cyclophosphamide , &lt; = 21 day first cycle plan regimen 2 . &gt; = 18 year age 3 . ECOG &lt; = 3 4 . Signed informed consent 5 . Measurable serum paraprotein SPEP serum free light chain ratio , quantifiable BenceJones proteinuria 24 hour urine specimen . If monoclonal protein merge beta region follow serum immunoglobulin involve heavy chain comment either partial remission ( PR , judge two protocol investigator ) complete remission ( CR , define achievement PR resolution monoclonal protein immunofixation serum urine . ) 1 . Failure sign inform consent 2 . Smoldering myeloma , monoclonal gammopathy undetermined significance ( MGUS ) , plasma cell leukemia 3 . History previously treat smolder myeloma 4 . Grade 3 peripheral neuropathy 5 . Uncontrolled human immunodeficiency virus ( HIV ) 6 . Active hepatitis A , B C 7 . Pregnant lactating female 8 . Total bilirubin &gt; 3 time upper limit normal 9 . ASLT/ALT &gt; 2.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>